Miltenyi Biotec acquires gene therapy assets from Lentigen

Global biotechnology company Miltenyi Biotec has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen, a provider of lentiviral technology for cell and gene therapy applications. Recent clinical trials have demonstrated that lentiviral technology provides the most efficient method for delivering genetic material into cells to modulate their function.

Assets obtained in the transaction include a broad range of intellectual property, process technologies and cGMP-qualified manufacturing facilities. The Lentigen team will join Miltenyi Biotec and operate through its newly formed, wholly owned US subsidiary Lentigen Technology. Seller Opus Bio has meanwhile been granted certain rights to deploy lentiviral technology in some therapeutic indications, for which Lentigen Technology shall be the preferred manufacturing supplier.

“It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale,” said Miltenyi Biotec CEO Stefan Miltenyi. “With the acquisition of the Lentigen assets, we have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner.”

Miltenyi Biotec will leverage the combined capabilities by offering customised system and application design in strategic partnerships with clinical investigators and companies to develop and commercialise cell and gene therapies.

Source